The mGlu5 receptor agonist CHPG stimulates striatal glutamate release: possible involvement of A2A receptors

Neuroreport. 2000 Nov 9;11(16):3611-4. doi: 10.1097/00001756-200011090-00042.

Abstract

The intrastriatal perfusion of the selective metabotropic glutamate (mGlu)5 receptor agonist (RS)-2-chloro-5-hydroxy-phenylglycine (CHPG, 1000 microM) significantly increased (approximately + 100%, p < 0.05) glutamate extracellular levels with respect to basal values. The potentiating effect of CHPG was prevented by the selective mGlu5 receptor antagonist 2-methyl-6(phenyl-ethynyl)-pyridine (MPEP, 250 microM)) and by the adenosine A2A receptor antagonist SCH 58261 (2 mg/kg, i.p.). The results show that mGlu5 receptors are involved in the regulation of striatal glutamate release and suggest an involvement of adenosine A2A receptors in mGlu5 receptor-mediated effects.

MeSH terms

  • Animals
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Excitatory Amino Acid Antagonists / pharmacology
  • Glutamic Acid / metabolism*
  • Glycine / analogs & derivatives*
  • Glycine / pharmacology
  • Male
  • Microdialysis
  • Neuroprotective Agents / pharmacology
  • Phenylacetates / pharmacology*
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate / agonists*
  • Receptors, Metabotropic Glutamate / antagonists & inhibitors
  • Receptors, Purinergic P1 / drug effects
  • Receptors, Purinergic P1 / physiology*
  • Triazoles / pharmacology

Substances

  • 2-chloro-5-hydroxyphenylglycine
  • 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
  • Excitatory Amino Acid Antagonists
  • Neuroprotective Agents
  • Phenylacetates
  • Pyridines
  • Pyrimidines
  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate
  • Receptors, Purinergic P1
  • Triazoles
  • Glutamic Acid
  • 6-methyl-2-(phenylethynyl)pyridine
  • Glycine